{"nctId":"NCT00345176","briefTitle":"Age-Related Eye Disease Study 2 (AREDS2)","startDateStruct":{"date":"2006-09"},"conditions":["Age-related Macular Degeneration","Cataract"],"count":4203,"armGroups":[{"label":"Lutein/Zeaxanthin","type":"ACTIVE_COMPARATOR","interventionNames":["Dietary Supplement: Lutein/zeaxanthin"]},{"label":"DHA/EPA","type":"ACTIVE_COMPARATOR","interventionNames":["Dietary Supplement: DHA/EPA"]},{"label":"Lutein/Zeaxanthin + DHA/EPA","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: Lutein/zeaxanthin and DHA/EPA"]},{"label":"Placebo/Control","type":"PLACEBO_COMPARATOR","interventionNames":[]}],"interventions":[{"name":"Lutein/zeaxanthin","otherNames":[]},{"name":"DHA/EPA","otherNames":["docosahexaenoic acid; eicosapentaenoic acid"]},{"name":"Lutein/zeaxanthin and DHA/EPA","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Men and women between the ages of 50 and 85 years\n* Macular status ranges from large drusen in both eyes or large drusen in one eye and advanced AMD (neovascular AMD or geographic atrophy) in the fellow eye\n\nExclusion Criteria:\n\n* Ocular media not clear enough to allow good fundus photography","healthyVolunteers":false,"sex":"ALL","minimumAge":"50 Years","maximumAge":"85 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Development of Advanced AMD in People at Moderate to High Risk for Progression.","description":"Defined as central geographic atrophy or retinal features of choroidal neovascularization detected on central grading of the stereoscopic fundus photographs or a history of treatment for advanced AMD after study enrollment.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"493","spread":null},{"groupId":"OG001","value":"468","spread":null},{"groupId":"OG002","value":"507","spread":null},{"groupId":"OG003","value":"472","spread":null}]}]}]},{"type":"SECONDARY","title":"Progression to Moderate Vision Loss","description":"Loss defined as \\>/= 3 lines of letters from baseline or treatment for choroidal neovascularization","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"515","spread":null},{"groupId":"OG001","value":"509","spread":null},{"groupId":"OG002","value":"519","spread":null},{"groupId":"OG003","value":"506","spread":null}]}]}]},{"type":"SECONDARY","title":"Adverse Events","description":"Safety outcomes included serious adverse events and mortality.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"81","spread":null},{"groupId":"OG001","value":"87","spread":null},{"groupId":"OG002","value":"96","spread":null},{"groupId":"OG003","value":"104","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"479","spread":null},{"groupId":"OG001","value":"484","spread":null},{"groupId":"OG002","value":"505","spread":null},{"groupId":"OG003","value":"519","spread":null}]}]}]},{"type":"SECONDARY","title":"Progression to Cataract Surgery","description":"The study examined the effects of lutein/zeaxanthin on progression to cataract surgery with data collected during regular telephone contacts and the annual study visits.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"708","spread":null},{"groupId":"OG001","value":"681","spread":null}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"Incident Cardiovascular Disease","description":"Effects of oral supplementation of omega-3 fatty acids, lutein/zeaxanthin on cardiovascular disease","classes":[]},{"type":"OTHER_PRE_SPECIFIED","title":"Cognition as Measured by a Telephone Battery","description":"Effects of oral supplementation of omega-3 fatty acids, lutein/zeaxanthin, zinc, and beta-carotene on cognitive function","classes":[]},{"type":"OTHER_PRE_SPECIFIED","title":"Prevalence of Peripheral Changes as Measured Using OPTOS Imaging","description":"Effects of oral supplementation of omega-3 fatty acids, lutein/zeaxanthin on the peripheral retina","classes":[]},{"type":"OTHER_PRE_SPECIFIED","title":"Genetics for the Association of AMD and Cataract","description":null,"classes":[]},{"type":"OTHER_PRE_SPECIFIED","title":"Genetics for the Progression of AMD and Cataract","description":null,"classes":[]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":479,"n":1012},"commonTop":["Vitreous disorder","Upper respiratory tract infection","Visual disturbance","Eye disorder","Urinary tract infection"]}}}